About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Tg(tetO-BRAF*V600E)26Jaf
transgene insertion 26, James A Fagin
MGI:5524276
Summary 1 genotype
Jump to Allelic Composition Genetic Background Genotype ID
cx1
Tg(tetO-BRAF*V600E)26Jaf/0
Tg(TG-rtTA)30Jaf/0
involves: FVB/N MGI:5524277


Genotype
MGI:5524277
cx1
Allelic
Composition
Tg(tetO-BRAF*V600E)26Jaf/0
Tg(TG-rtTA)30Jaf/0
Genetic
Background
involves: FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• after 1 week exposure to doxycycline (dox), mutants show an 8-fold increase in thyroid mass, which regresses by 72 hours and reaches normal size by 7 weeks after dox withdrawal
• none of the mutants, however, develop thyroid abnormalities in the absence of doxycycline
• after 1 week exposure to dox, all mutants develop thyroid cancer characterized by solid nests of tumor cells without follicular architecture or colloid formation
• tumors of mutants exposed to dox exhibit nuclear enlargement, crowding and overlapping, irregularity of nuclear contours and occasional nuclear grooves, characteristics seen in human papillary thyroid carcinoma
• 3 of 8 mutants with poorly differentiated thyroid cancer show extrathyroidal extension of the tumor
• however, no lymph node or distant metastases are seen
• two weeks after dox withdrawal, thyroid glands of mutants are normal or have hyperplastic features and by 7 weeks off dox, all mice have normal thyroid histology
• an increase in apoptosis is seen within the center of the thyroid tumors within 72 hours of dox withdrawal and is no longer seen by 2 weeks
• treatment of dox induced thyroid tumors with PD0325901, a small molecule MEK inhibitor, or PLX4720 or PLX4032, selective inhibitors of BRAF, fails to induce tumor regression, although expression of thyroid-specific genes is partially restored and the BRAF inhibitors inhibit the proliferative index of tumors and renders tumor cells susceptible to radioiodine treatment
• mutants become hypothyroid within 48 hours of dox administration, showing decreased serum T4 and thyrotrophin (TSH) levels
• removal of dox results in normalization of thyroid function

homeostasis/metabolism
• within 48 hours of dox administration, mutants show decreased serum T4 levels
• within 48 hours of dox administration, mutants show decreased serum thyrotrophin levels

neoplasm
• after 1 week exposure to dox, all mutants develop thyroid cancer characterized by solid nests of tumor cells without follicular architecture or colloid formation
• tumors of mutants exposed to dox exhibit nuclear enlargement, crowding and overlapping, irregularity of nuclear contours and occasional nuclear grooves, characteristics seen in human papillary thyroid carcinoma
• 3 of 8 mutants with poorly differentiated thyroid cancer show extrathyroidal extension of the tumor
• however, no lymph node or distant metastases are seen
• two weeks after dox withdrawal, thyroid glands of mutants are normal or have hyperplastic features and by 7 weeks off dox, all mice have normal thyroid histology
• an increase in apoptosis is seen within the center of the thyroid tumors within 72 hours of dox withdrawal and is no longer seen by 2 weeks
• treatment of dox induced thyroid tumors with PD0325901, a small molecule MEK inhibitor, or PLX4720 or PLX4032, selective inhibitors of BRAF, fails to induce tumor regression, although expression of thyroid-specific genes is partially restored and the BRAF inhibitors inhibit the proliferative index of tumors and renders tumor cells susceptible to radioiodine treatment

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
papillary thyroid carcinoma DOID:3969 OMIM:188550
J:184420





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
11/05/2024
MGI 6.24
The Jackson Laboratory